Evidence map›Paper›PMID 42887291›Full record

ArticleClinics (Sao Paulo, Brazil)2026

Gut mycobiome in the spectrum of Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD): from MASH to hepatocellular carcinoma.

Cássio Marques Perlin, Melina Belén Keingeski, Bruno de Souza Basso, Beatriz Garcia Mendes, Julliane Dutra Medeiros, Francis Moreira Borges, Bernd Schnabl, Mário Reis Álvares-da-Silva

Abstract read
PubMed Publisher
In one paragraph

Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cássio Marques PerlinGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS Brazil; Experimental Laboratory of Hepatology and Gastroenterology, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Melina Belén KeingeskiGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS Brazil; Experimental Laboratory of Hepatology and Gastroenterology, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Bruno de Souza BassoGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS Brazil; Experimental Laboratory of Hepatology and Gastroenterology, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil.
Beatriz Garcia MendesDepartment of Clinical Analysis, Universidade Federal de Santa Catarina, Florianopolis, SC, Brazil.
Julliane Dutra MedeirosLaboratory of Bacterial Physiology and Microbial Molecular Genetics, Department of Parasitology, Microbiology and Immunology, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
Francis Moreira BorgesLaboratory of Bacterial Physiology and Microbial Molecular Genetics, Department of Parasitology, Microbiology and Immunology, Universidade Federal de Juiz de Fora, Juiz de Fora, MG, Brazil.
Bernd SchnablSan Diego Digestive Diseases Research, Center University of California San Diego, USA.
Mário Reis Álvares-da-SilvaGraduate Program in Gastroenterology and Hepatology, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS Brazil; Experimental Laboratory of Hepatology and Gastroenterology, Experimental Research Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil; School of Medicine, Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Division of Gastroenterology, Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil. Electronic address: brunods.basso@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gut Microbiome (GM) dysbiosis is associated with the development and progression of Metabolic-dysfunction Associated Steatotic Liver Disease (MASLD) and steatohepatitis (MASH). Human GM contains bacteria, fungi, archaea, and viruses. Gut mycobiome (GMyco) is still poorly studied in patients with MASLD. Herein we investigated GMyco composition at different MASLD stages.

methods23 patients were recruited: controls (n = 5); MASH (n = 6); cirrhosis (n = 7); and Hepatocellular Carcinoma (HCC) (n = 5). Stool samples were collected and stored in -80 °C for subsequent DNA extraction and profiled by 18S rRNA sequencing. The single sequence variants obtained were inferred with DADA2 and classified with SILVA v138. Diversity metrics (Simpson; Bray-Curtis PERMANOVA) and DESeq2 with BH FDR were used for statistical analysis.

resultsAmong 23 participants, 73.9% were women, and the average BMI was 30.7 kg/m

conclusionsThe gut mycobiota profile varied across the MASLD spectrum, with stage-specific enrichment of certain taxa despite overall similarity in community structure. Basidiomycetes ‒ notably Malassezia and Naganishia ‒ were more abundant in MASH, while Saccharomyces dominated in advanced stages. These findings suggest that distinct fungal signatures accompany disease progression and may serve as potential biological markers in MASLD.

Indexed as

Gut mycobiomeLiver FibrosisMetabolic-Dysfunction Associated Steatotic Liver Disease (MASLD)

Identifiers

PMID42887291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.